{"rows":[{"id":301,"title":"Contribution of the Serotonin 5-HT2A Receptor to the Therapeutic Effect of Psilocin on Social Behavior Deficits in Mice Repeatedly Exposed to Social Defeat Stress","authors":"Ibi Daisuke, Takaba Rika, Yoshida Keisuke, Kawase Ririna, Kitagawa Hiroko, Matsushita Momoko, Ito Kana, Uno Shoya, Nishimura Fumiya, Kitagaki Shinji, Hiramatsu Masayuki","journal":"Neuropsychopharmacology Reports","publication_date":"2026-08-31","publication_year":2026,"doi":"10.1002/npr2.70152","pubmed_id":"42379141","openalex_id":"https://openalex.org/W7166665532","source_url":"https://doi.org/10.1002/npr2.70152","substance_tags":"psilocybin,psilocin","topic_tags":"Depression,Anxiety,Receptor Pharmacology,Resilience,Animal Study,Treatment-Resistant Depression","study_type":"Animal Study","source_name":"Crossref","publication_status":"published","date_added":"2026-07-01 06:48:03","last_checked":"2026-07-07 01:20:41","bibtex":null,"source_record_id":"PMID:42379141","abstract_available":true,"abstract_source":"Crossref","abstract_source_url":"https://doi.org/10.1002/npr2.70152","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"Crossref","source_record_id":"PMID:42379141","source_url":"https://doi.org/10.1002/npr2.70152","doi":"10.1002/npr2.70152","pmid":"42379141","publication_date":"2026-08-31","importer_version":"2.1.3","text_redistributed":false}},{"id":1922,"title":"Phase 1 trial suggests benefit of psilocybin in OCD treatment","authors":"","journal":"The Brown University Psychopharmacology Update","publication_date":"2026-07-31","publication_year":2026,"doi":"10.1002/pu.31474","pubmed_id":null,"openalex_id":"https://openalex.org/W7166436628","source_url":"https://doi.org/10.1002/pu.31474","substance_tags":"psilocybin","topic_tags":"OCD,Clinical Trial,Adverse Events","study_type":"Clinical Trial","source_name":"Crossref","publication_status":"published","date_added":"2026-07-01 06:49:23","last_checked":"2026-07-05 01:20:21","bibtex":null,"source_record_id":"DOI:10.1002/pu.31474","abstract_available":true,"abstract_source":"Crossref","abstract_source_url":"https://doi.org/10.1002/pu.31474","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"Crossref","source_record_id":"DOI:10.1002/pu.31474","source_url":"https://doi.org/10.1002/pu.31474","doi":"10.1002/pu.31474","pmid":"","publication_date":"2026-07-31","importer_version":"2.1.3","text_redistributed":false}},{"id":5739,"title":"Psilocybin asymmetrically modulates outcome-based choice and cortical processing under uncertainty","authors":"Jacobs, D. S.; Pacheco, A. T.; Olson, R.; Langdon, A. J.; Moghaddam, B.","journal":"bioRxiv","publication_date":"2026-07-20","publication_year":2026,"doi":"10.64898/2026.07.16.733837","pubmed_id":null,"openalex_id":null,"source_url":"https://doi.org/10.64898/2026.07.16.733837","substance_tags":"psilocybin","topic_tags":"General","study_type":"Other","source_name":"bioRxiv","publication_status":"preprint","date_added":"2026-07-22 01:20:20","last_checked":"2026-07-22 01:27:16","bibtex":null,"source_record_id":"DOI:10.64898/2026.07.16.733837","abstract_available":true,"abstract_source":"bioRxiv","abstract_source_url":"https://doi.org/10.64898/2026.07.16.733837","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"bioRxiv","source_record_id":"DOI:10.64898/2026.07.16.733837","source_url":"https://doi.org/10.64898/2026.07.16.733837","doi":"10.64898/2026.07.16.733837","pmid":"","publication_date":"2026-07-20","importer_version":"2.1.3","text_redistributed":false}},{"id":3686,"title":"PRISMatic: A Phase 1b Randomized, Double-Armed, Parallel-Group, Placebo-Controlled Trial of Psilocybin Efficacy With or Without Pimavanserin Pretreatment","authors":"Johns Hopkins University","journal":"ClinicalTrials.gov","publication_date":"2026-07-20","publication_year":2026,"doi":null,"pubmed_id":null,"openalex_id":null,"source_url":"https://clinicaltrials.gov/study/NCT07610135","substance_tags":"psilocybin","topic_tags":"Brain Imaging,Pharmacology,Mechanism of Action,Receptor Pharmacology,Biomarkers,Wellbeing,Clinical Trial","study_type":"Clinical Trial","source_name":"ClinicalTrials.gov","publication_status":"clinical trial","date_added":"2026-07-01 11:04:28","last_checked":"2026-07-22 01:27:46","bibtex":null,"source_record_id":"https://clinicaltrials.gov/study/NCT07610135","abstract_available":true,"abstract_source":"ClinicalTrials.gov","abstract_source_url":"https://clinicaltrials.gov/study/NCT07610135","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"ClinicalTrials.gov","source_record_id":"https://clinicaltrials.gov/study/NCT07610135","source_url":"https://clinicaltrials.gov/study/NCT07610135","doi":"","pmid":"","publication_date":"2026-07-20","importer_version":"2.1.3","text_redistributed":false}},{"id":3522,"title":"Psilocybin-Assisted Therapy for Physician Well-Being and Burnout: Feasibility, Safety, Clinical Effectiveness and Biomarkers of Response [PAT-B (Psilocybin-Assisted Therapy for Physician Well-Being and Burnout)]","authors":"University of California, San Diego","journal":"ClinicalTrials.gov","publication_date":"2026-07-20","publication_year":2026,"doi":null,"pubmed_id":null,"openalex_id":null,"source_url":"https://clinicaltrials.gov/study/NCT06814522","substance_tags":"psilocybin","topic_tags":"Depression,Addiction,Brain Imaging,Biomarkers,Wellbeing,Emotional Processing,Healthcare Workers,Safety","study_type":"Other","source_name":"ClinicalTrials.gov","publication_status":"clinical trial","date_added":"2026-07-01 11:04:27","last_checked":"2026-07-22 01:27:46","bibtex":null,"source_record_id":"https://clinicaltrials.gov/study/NCT06814522","abstract_available":true,"abstract_source":"ClinicalTrials.gov","abstract_source_url":"https://clinicaltrials.gov/study/NCT06814522","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"ClinicalTrials.gov","source_record_id":"https://clinicaltrials.gov/study/NCT06814522","source_url":"https://clinicaltrials.gov/study/NCT06814522","doi":"","pmid":"","publication_date":"2026-07-20","importer_version":"2.1.3","text_redistributed":false}},{"id":5738,"title":"Psychedelic drug action at dendrites is gated by behavioral state and serotonin receptors","authors":"Savalia, N.; Shao, L.-X.; Knox, C. A.; Gilbert, A. D.; Jiang, Q.; Kwan, A. C.","journal":"bioRxiv","publication_date":"2026-07-19","publication_year":2026,"doi":"10.64898/2026.07.16.738983","pubmed_id":null,"openalex_id":null,"source_url":"https://doi.org/10.64898/2026.07.16.738983","substance_tags":"psilocybin","topic_tags":"Neuroplasticity,Pharmacology,Mechanism of Action,Receptor Pharmacology,Animal Study","study_type":"Animal Study","source_name":"bioRxiv","publication_status":"preprint","date_added":"2026-07-21 01:26:00","last_checked":"2026-07-22 01:27:16","bibtex":null,"source_record_id":"DOI:10.64898/2026.07.16.738983","abstract_available":true,"abstract_source":"bioRxiv","abstract_source_url":"https://doi.org/10.64898/2026.07.16.738983","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"bioRxiv","source_record_id":"DOI:10.64898/2026.07.16.738983","source_url":"https://doi.org/10.64898/2026.07.16.738983","doi":"10.64898/2026.07.16.738983","pmid":"","publication_date":"2026-07-19","importer_version":"2.1.3","text_redistributed":false}},{"id":5737,"title":"Learnings from a hybrid communities of practice group therapy model to support psilocybin-assisted therapy for patients with a terminal diagnosis","authors":"Tsang Vivian WL, Kryskow Pamela, Watler Crosbie, Allard Pearl, Dames Shannon","journal":"Frontiers in Public Health","publication_date":"2026-07-19","publication_year":2026,"doi":"10.3389/fpubh.2026.1767215","pubmed_id":null,"openalex_id":"https://openalex.org/W7169758970","source_url":"https://doi.org/10.3389/fpubh.2026.1767215","substance_tags":"psilocybin","topic_tags":"End-of-Life Distress,Resilience,Observational Study,Cancer Patients,Safety","study_type":"Observational Study","source_name":"Crossref","publication_status":"published","date_added":"2026-07-21 01:20:20","last_checked":"2026-07-22 01:20:24","bibtex":null,"source_record_id":"DOI:10.3389/fpubh.2026.1767215","abstract_available":true,"abstract_source":"Crossref","abstract_source_url":"https://doi.org/10.3389/fpubh.2026.1767215","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"Crossref","source_record_id":"DOI:10.3389/fpubh.2026.1767215","source_url":"https://doi.org/10.3389/fpubh.2026.1767215","doi":"10.3389/fpubh.2026.1767215","pmid":"","publication_date":"2026-07-19","importer_version":"2.1.3","text_redistributed":false}},{"id":3561,"title":"The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease","authors":"Yale University","journal":"ClinicalTrials.gov","publication_date":"2026-07-19","publication_year":2026,"doi":null,"pubmed_id":null,"openalex_id":null,"source_url":"https://clinicaltrials.gov/study/NCT07610369","substance_tags":"psilocybin","topic_tags":"Depression,Microdosing,Randomized Controlled Trial,Safety","study_type":"Randomized Controlled Trial","source_name":"ClinicalTrials.gov","publication_status":"clinical trial","date_added":"2026-07-01 11:04:28","last_checked":"2026-07-22 01:27:46","bibtex":null,"source_record_id":"https://clinicaltrials.gov/study/NCT07610369","abstract_available":true,"abstract_source":"ClinicalTrials.gov","abstract_source_url":"https://clinicaltrials.gov/study/NCT07610369","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"ClinicalTrials.gov","source_record_id":"https://clinicaltrials.gov/study/NCT07610369","source_url":"https://clinicaltrials.gov/study/NCT07610369","doi":"","pmid":"","publication_date":"2026-07-19","importer_version":"2.1.3","text_redistributed":false}},{"id":5736,"title":"A randomized, double-blind, placebo-controlled single-ascending-dose study to identify a non-hallucinogenic dose of psilocybin in healthy adults.","authors":"Levy-Cooperman, N.; Sellers, E.; Glue, P.; Szeto, I.; Brown, D.; Jarecki-Smith, J.; Tyler, W. J.; McDonnell, M. B.","journal":"medRxiv","publication_date":"2026-07-18","publication_year":2026,"doi":"10.64898/2026.07.16.26358273","pubmed_id":null,"openalex_id":null,"source_url":"https://doi.org/10.64898/2026.07.16.26358273","substance_tags":"psilocybin,psilocin","topic_tags":"Anxiety,End-of-Life Distress,Pharmacology,Clinical Trial,Review Article,Observational Study,Safety,Adverse Events","study_type":"Clinical Trial","source_name":"medRxiv","publication_status":"preprint","date_added":"2026-07-20 01:20:48","last_checked":"2026-07-22 01:20:53","bibtex":null,"source_record_id":"DOI:10.64898/2026.07.16.26358273","abstract_available":true,"abstract_source":"medRxiv","abstract_source_url":"https://doi.org/10.64898/2026.07.16.26358273","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"medRxiv","source_record_id":"DOI:10.64898/2026.07.16.26358273","source_url":"https://doi.org/10.64898/2026.07.16.26358273","doi":"10.64898/2026.07.16.26358273","pmid":"","publication_date":"2026-07-18","importer_version":"2.1.3","text_redistributed":false}},{"id":5733,"title":"Quantifying psilocybin exposure in a natural product-based retreat setting: An observational field method for dose measurement","authors":"Sergio Pérez Rosal, Sonya C. Faber","journal":"Psychedelics","publication_date":"2026-07-17","publication_year":2026,"doi":"10.1016/j.psyche.2026.100029","pubmed_id":null,"openalex_id":"https://openalex.org/W7169607828","source_url":"https://doi.org/10.1016/j.psyche.2026.100029","substance_tags":"psilocybin","topic_tags":"Observational Study,Safety,Adverse Events,Toxicity","study_type":"Observational Study","source_name":"OpenAlex","publication_status":"published","date_added":"2026-07-19 01:20:13","last_checked":"2026-07-22 01:20:24","bibtex":null,"source_record_id":"DOI:10.1016/j.psyche.2026.100029","abstract_available":true,"abstract_source":"OpenAlex","abstract_source_url":"https://doi.org/10.1016/j.psyche.2026.100029","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"OpenAlex","source_record_id":"DOI:10.1016/j.psyche.2026.100029","source_url":"https://doi.org/10.1016/j.psyche.2026.100029","doi":"10.1016/j.psyche.2026.100029","pmid":"","publication_date":"2026-07-17","importer_version":"2.1.3","text_redistributed":false}},{"id":5732,"title":"Psilocybin produces amplified acute responses and sex-specific long-term increases in sensorimotor gating in the mGlu5 knockout mouse model of schizophrenia.","authors":"Gattuso JJ, Kamal A, Payet JM, Havaux K, Hendey J, Bezcioglu B, Phelan ZJ, Orchard M, Bhanot D, Hale MW, Hannan AJ, Renoir T.","journal":"Neuropsychopharmacology","publication_date":"2026-07-17","publication_year":2026,"doi":"10.1038/s41386-026-02501-3","pubmed_id":"42471435","openalex_id":"https://openalex.org/W7169664384","source_url":"https://doi.org/10.1038/s41386-026-02501-3","substance_tags":"psilocybin","topic_tags":"Anxiety,Mechanism of Action,Receptor Pharmacology,Animal Study,Drug Interactions","study_type":"Animal Study","source_name":"Europe PMC","publication_status":"published","date_added":"2026-07-19 01:20:09","last_checked":"2026-07-22 01:20:24","bibtex":null,"source_record_id":"PMID:42471435","abstract_available":true,"abstract_source":"Europe PMC","abstract_source_url":"https://doi.org/10.1038/s41386-026-02501-3","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"Europe PMC","source_record_id":"PMID:42471435","source_url":"https://doi.org/10.1038/s41386-026-02501-3","doi":"10.1038/s41386-026-02501-3","pmid":"42471435","publication_date":"2026-07-17","importer_version":"2.1.3","text_redistributed":false}},{"id":5734,"title":"Beyond Monoamines: Ketamine, Esketamine, and Classic Psychedelics in the Treatment of Depression","authors":"Bartosz Niciński, Magdalena Kloc, Ewa Wiench, Natasza Millan, Aleksandra Blicharz, Wojciech Kozdraś, Lidia Kozaczko, Gabriela Szewczyk, Elżbieta Bukowczan, Alicja Zając, Damian Broda, Alicja Benecka","journal":"Zenodo (CERN European Organization for Nuclear Research)","publication_date":"2026-07-16","publication_year":2026,"doi":"10.5281/zenodo.21406174","pubmed_id":null,"openalex_id":"https://openalex.org/W7169604178","source_url":"https://doi.org/10.5281/zenodo.21406174","substance_tags":"psilocybin","topic_tags":"Depression,Neuroplasticity,Mechanism of Action,Receptor Pharmacology,Clinical Trial,Review Article,Animal Study,Treatment-Resistant Depression,Safety,Toxicity","study_type":"Clinical Trial","source_name":"OpenAlex","publication_status":"published","date_added":"2026-07-19 01:20:13","last_checked":"2026-07-22 01:20:25","bibtex":null,"source_record_id":"DOI:10.5281/zenodo.21406174","abstract_available":true,"abstract_source":"OpenAlex","abstract_source_url":"https://doi.org/10.5281/zenodo.21406174","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"OpenAlex","source_record_id":"DOI:10.5281/zenodo.21406174","source_url":"https://doi.org/10.5281/zenodo.21406174","doi":"10.5281/zenodo.21406174","pmid":"","publication_date":"2026-07-16","importer_version":"2.1.3","text_redistributed":false}},{"id":5731,"title":"A Randomized, Double-Blind, Single Ascending Dose Study to Identify a Safe and Non-Psychedelic Dose of Psilocybin","authors":"Diamond Therapeutics Inc.","journal":"ClinicalTrials.gov","publication_date":"2026-07-16","publication_year":2026,"doi":null,"pubmed_id":null,"openalex_id":null,"source_url":"https://clinicaltrials.gov/study/NCT07710027","substance_tags":"psilocybin,psilocin","topic_tags":"Depression,Anxiety,Addiction,Pharmacology,Receptor Pharmacology,Biomarkers,Review Article,Observational Study,Healthy Volunteers,Safety,Adverse Events","study_type":"Clinical Trial","source_name":"ClinicalTrials.gov","publication_status":"clinical trial","date_added":"2026-07-18 01:24:24","last_checked":"2026-07-22 01:27:46","bibtex":null,"source_record_id":"https://clinicaltrials.gov/study/NCT07710027","abstract_available":true,"abstract_source":"ClinicalTrials.gov","abstract_source_url":"https://clinicaltrials.gov/study/NCT07710027","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"ClinicalTrials.gov","source_record_id":"https://clinicaltrials.gov/study/NCT07710027","source_url":"https://clinicaltrials.gov/study/NCT07710027","doi":"","pmid":"","publication_date":"2026-07-16","importer_version":"2.1.3","text_redistributed":false}},{"id":5730,"title":"Publication bias in randomized trials of psilocybin for depression: a Robust Bayesian Meta-Analysis","authors":"","journal":"PsyArXiv","publication_date":"2026-07-16","publication_year":2026,"doi":null,"pubmed_id":null,"openalex_id":null,"source_url":"https://osf.io/preprints/psyarxiv/6gy8v_v1","substance_tags":"psilocybin","topic_tags":"Depression,Pharmacology,Randomized Controlled Trial,Meta-Analysis,Systematic Review,Review Article","study_type":"Randomized Controlled Trial","source_name":"PsyArXiv","publication_status":"preprint","date_added":"2026-07-18 01:24:20","last_checked":"2026-07-22 01:27:43","bibtex":null,"source_record_id":"https://osf.io/preprints/psyarxiv/6gy8v_v1","abstract_available":true,"abstract_source":"PsyArXiv","abstract_source_url":"https://osf.io/preprints/psyarxiv/6gy8v_v1","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"PsyArXiv","source_record_id":"https://osf.io/preprints/psyarxiv/6gy8v_v1","source_url":"https://osf.io/preprints/psyarxiv/6gy8v_v1","doi":"","pmid":"","publication_date":"2026-07-16","importer_version":"2.1.3","text_redistributed":false}},{"id":3691,"title":"Outpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder: a Randomized Double-blind Trial","authors":"Johns Hopkins University","journal":"ClinicalTrials.gov","publication_date":"2026-07-16","publication_year":2026,"doi":null,"pubmed_id":null,"openalex_id":null,"source_url":"https://clinicaltrials.gov/study/NCT06067737","substance_tags":"psilocybin","topic_tags":"Addiction,Pharmacology,Clinical Trial,Randomized Controlled Trial,Healthy Volunteers,Healthcare Workers,Adverse Events","study_type":"Randomized Controlled Trial","source_name":"ClinicalTrials.gov","publication_status":"clinical trial","date_added":"2026-07-01 11:04:28","last_checked":"2026-07-22 01:27:46","bibtex":null,"source_record_id":"https://clinicaltrials.gov/study/NCT06067737","abstract_available":true,"abstract_source":"ClinicalTrials.gov","abstract_source_url":"https://clinicaltrials.gov/study/NCT06067737","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"ClinicalTrials.gov","source_record_id":"https://clinicaltrials.gov/study/NCT06067737","source_url":"https://clinicaltrials.gov/study/NCT06067737","doi":"","pmid":"","publication_date":"2026-07-16","importer_version":"2.1.3","text_redistributed":false}},{"id":3539,"title":"The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder","authors":"Sharmin Ghaznavi","journal":"ClinicalTrials.gov","publication_date":"2026-07-16","publication_year":2026,"doi":null,"pubmed_id":null,"openalex_id":null,"source_url":"https://clinicaltrials.gov/study/NCT06247839","substance_tags":"psilocybin","topic_tags":"Depression,Brain Imaging,Aging","study_type":"Other","source_name":"ClinicalTrials.gov","publication_status":"clinical trial","date_added":"2026-07-01 11:04:28","last_checked":"2026-07-22 01:27:46","bibtex":null,"source_record_id":"https://clinicaltrials.gov/study/NCT06247839","abstract_available":true,"abstract_source":"ClinicalTrials.gov","abstract_source_url":"https://clinicaltrials.gov/study/NCT06247839","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"ClinicalTrials.gov","source_record_id":"https://clinicaltrials.gov/study/NCT06247839","source_url":"https://clinicaltrials.gov/study/NCT06247839","doi":"","pmid":"","publication_date":"2026-07-16","importer_version":"2.1.3","text_redistributed":false}},{"id":5735,"title":"Psychedelic Therapies in the Management of Post-Traumatic Stress Disorder","authors":"Jakub Bajer, Aleksandra Włodarczyk, Hubert Kulawinek, Julia Obersztyn, Krzysztof Kasparek, Marta Czech, Grzegorz Kasparek, Adrianna Szczecińska, Wiktoria Glanert, Aleksandra Mliczek, Piotr Mrozek","journal":"Journal of Education Health and Sport","publication_date":"2026-07-15","publication_year":2026,"doi":"10.12775/jehs.2026.94.73071","pubmed_id":null,"openalex_id":"https://openalex.org/W7169523177","source_url":"https://doi.org/10.12775/jehs.2026.94.73071","substance_tags":"psilocybin","topic_tags":"Depression,Anxiety,PTSD,Neuroplasticity,Mechanism of Action,Receptor Pharmacology,Clinical Trial,Review Article,Treatment-Resistant Depression,Safety,Toxicity","study_type":"Clinical Trial","source_name":"OpenAlex","publication_status":"published","date_added":"2026-07-19 01:20:13","last_checked":"2026-07-22 01:20:25","bibtex":null,"source_record_id":"DOI:10.12775/jehs.2026.94.73071","abstract_available":true,"abstract_source":"OpenAlex","abstract_source_url":"https://doi.org/10.12775/jehs.2026.94.73071","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"OpenAlex","source_record_id":"DOI:10.12775/jehs.2026.94.73071","source_url":"https://doi.org/10.12775/jehs.2026.94.73071","doi":"10.12775/jehs.2026.94.73071","pmid":"","publication_date":"2026-07-15","importer_version":"2.1.3","text_redistributed":false}},{"id":5728,"title":"Integrated 5-HT2A-TrkB and G protein signaling in serotonergic psychedelic responses.","authors":"Taddei-Tardón M, Medina-Rodríguez L, Maltman JL, Hudson S, Potukanuma S, Hidalgo Jiménez J, Martín-Guerrero SM, González-Maeso J, López-Giménez JF.","journal":null,"publication_date":"2026-07-15","publication_year":2026,"doi":"10.1038/s41380-026-03746-6","pubmed_id":"42463904","openalex_id":null,"source_url":"https://doi.org/10.1038/s41380-026-03746-6","substance_tags":"psilocin","topic_tags":"Neuroplasticity,Pharmacology,Mechanism of Action,Receptor Pharmacology,In Vitro Study","study_type":"In Vitro Study","source_name":"Europe PMC","publication_status":"published","date_added":"2026-07-18 01:20:04","last_checked":"2026-07-22 01:20:21","bibtex":null,"source_record_id":"PMID:42463904","abstract_available":true,"abstract_source":"Europe PMC","abstract_source_url":"https://doi.org/10.1038/s41380-026-03746-6","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"Europe PMC","source_record_id":"PMID:42463904","source_url":"https://doi.org/10.1038/s41380-026-03746-6","doi":"10.1038/s41380-026-03746-6","pmid":"42463904","publication_date":"2026-07-15","importer_version":"2.1.3","text_redistributed":false}},{"id":5726,"title":"Uncovering the spatiotemporal structure of neural avalanches through optimal transport and dynamic time warping","authors":"Novicky, F.; Jajcay, N.; Hlinka, J.","journal":"bioRxiv","publication_date":"2026-07-15","publication_year":2026,"doi":"10.64898/2026.07.10.737743","pubmed_id":null,"openalex_id":null,"source_url":"https://doi.org/10.64898/2026.07.10.737743","substance_tags":"psilocybin","topic_tags":"Brain Imaging","study_type":"Other","source_name":"bioRxiv","publication_status":"preprint","date_added":"2026-07-17 01:20:10","last_checked":"2026-07-22 01:27:16","bibtex":null,"source_record_id":"DOI:10.64898/2026.07.10.737743","abstract_available":true,"abstract_source":"bioRxiv","abstract_source_url":"https://doi.org/10.64898/2026.07.10.737743","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"bioRxiv","source_record_id":"DOI:10.64898/2026.07.10.737743","source_url":"https://doi.org/10.64898/2026.07.10.737743","doi":"10.64898/2026.07.10.737743","pmid":"","publication_date":"2026-07-15","importer_version":"2.1.3","text_redistributed":false}},{"id":5725,"title":"Silence is golden: Documenting the speech production of participants and support providers in psilocybin administration sessions for the treatment of post-traumatic stress disorder.","authors":"Dougherty RF, Modlin NL, McGowan NM, Staples P, Williams E, Clarke P, Shafiei M, Leininger C, Alti M, Croal M, Marwood L, Kirlić N, Ryslik GA, Goodwin GM.","journal":"Journal of Psychopharmacology","publication_date":"2026-07-15","publication_year":2026,"doi":"10.1177/02698811261464988","pubmed_id":"42460632","openalex_id":"https://openalex.org/W7169098728","source_url":"https://doi.org/10.1177/02698811261464988","substance_tags":"psilocybin","topic_tags":"PTSD,Consciousness,Clinical Trial,Drug Interactions","study_type":"Clinical Trial","source_name":"Europe PMC","publication_status":"published","date_added":"2026-07-17 01:20:04","last_checked":"2026-07-22 01:20:25","bibtex":null,"source_record_id":"PMID:42460632","abstract_available":true,"abstract_source":"Europe PMC","abstract_source_url":"https://doi.org/10.1177/02698811261464988","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"Europe PMC","source_record_id":"PMID:42460632","source_url":"https://doi.org/10.1177/02698811261464988","doi":"10.1177/02698811261464988","pmid":"42460632","publication_date":"2026-07-15","importer_version":"2.1.3","text_redistributed":false}}],"total":4932,"page":1,"per_page":20,"pages":247,"resource":"papers","filters":{"q":null,"author":null,"substances":["psilocybin","psilocin"],"topic":null,"study_type":null,"cited_doi":null,"sources":[],"publication_statuses":[],"year":null,"journal":null,"from":null,"to":null,"added_from":null,"added_to":null,"sort":"newest","page":1,"per_page":"20"}}